Home › Trials › NCT06934226

Assessing JNJ-77242113 for treating moderate to severe plaque psoriasis

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis

Phase 3 Interventional Janssen Research & Development, LLC · NCT06934226

This study is testing a new medication called JNJ-77242113 to see if it can help people with moderate to severe plaque psoriasis feel better compared to a placebo and an existing treatment.

Quick facts

PhasePhase 3
Study typeInterventional
Enrollment675 (estimated)
Ages12 Years and up
SexAll
SponsorJanssen Research & Development, LLC Industry-sponsored
Drugs / interventionsustekinumab
Locations116 sites (Birmingham, Alabama and 115 other locations)
Trial IDNCT06934226 on ClinicalTrials.gov

What this trial studies

This study evaluates the efficacy and safety of JNJ-77242113 compared to a placebo and ustekinumab in individuals with moderate to severe plaque psoriasis. Participants will be assessed based on their total body surface area affected by psoriasis and severity scores. The study aims to determine how well JNJ-77242113 performs in alleviating symptoms compared to existing treatments. It is a Phase 3 interventional trial, indicating a focus on confirming effectiveness and monitoring side effects.

Who should consider this trial

Good fit: Ideal candidates include individuals diagnosed with moderate to severe plaque psoriasis, with a significant body surface area affected.

Not a fit: Patients with nonplaque forms of psoriasis or those with drug-induced psoriasis may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new effective option for patients suffering from moderate to severe plaque psoriasis.

How similar studies have performed: Previous studies have shown promise in treating plaque psoriasis with similar biologic approaches, indicating potential for success.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
* Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
* Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
* Total investigator global assessment (IGA) \>=3 at screening and baseline
* Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

* Nonplaque form of psoriasis (for example \[e.g.\], erythrodermic, guttate, or pustular)
* Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
* Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
* Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
* Transplanted organ (with exception of a corneal transplant greater than \[\>\] 12 weeks before the first administration of study intervention)

Where this trial is running

Birmingham, Alabama and 115 other locations

+66 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Plaque Psoriasis
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.